Your browser is no longer supported. Please, upgrade your browser.
Settings
ENOB Enochian Biosciences Inc. daily Stock Chart
ENOB [NASD]
Enochian Biosciences Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own0.10% Shs Outstand38.67M Perf Week0.14%
Market Cap270.69M Forward P/E- EPS next Y- Insider Trans- Shs Float13.82M Perf Month-3.98%
Income-28.10M PEG- EPS next Q- Inst Own- Short Float0.23% Perf Quarter9.38%
Sales- P/S- EPS this Y-138.80% Inst Trans- Short Ratio0.45 Perf Half Y21.74%
Book/sh4.11 P/B1.70 EPS next Y- ROA-16.70% Target Price- Perf Year12.00%
Cash/sh0.34 P/C20.51 EPS next 5Y- ROE-18.70% 52W Range3.32 - 9.50 Perf YTD0.00%
Dividend- P/FCF- EPS past 5Y-8.80% ROI- 52W High-24.21% Beta0.68
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low116.87% ATR0.53
Employees2 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)52.03 Volatility4.96% 8.09%
OptionableNo Debt/Eq0.00 EPS Q/Q-540.00% Profit Margin- Rel Volume0.29 Prev Close7.00
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume72.43K Price7.20
Recom- SMA204.98% SMA50-2.00% SMA20018.81% Volume15,553 Change2.86%
Mar-07-19 12:45PM  Successful Treatment of London Patient Underscores Clinical Potential of Enochian Biosciences Gene Modified Cellular Therapy for HIV GlobeNewswire -6.88%
Feb-01-19 02:31PM  4 Healthcare Stocks Looking To Start February Off Strong ACCESSWIRE +9.88%
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +10.00%
Jan-07-19 08:30AM  Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair GlobeNewswire
Jan-04-19 08:00AM  How Much Of Enochian Biosciences Inc. (NASDAQ:ENOB) Do Insiders Own? Simply Wall St.
Dec-05-18 08:30AM  Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol ENOB GlobeNewswire
Dec-03-18 08:30AM  Enochian Biosciences to Present at Biotech Showcase 2019 GlobeNewswire
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.